DE69635482D1 - Säugetieren apoptosis inhibitorprotein genfamilie, primers, probes und verfahren zur nachweis - Google Patents

Säugetieren apoptosis inhibitorprotein genfamilie, primers, probes und verfahren zur nachweis

Info

Publication number
DE69635482D1
DE69635482D1 DE69635482T DE69635482T DE69635482D1 DE 69635482 D1 DE69635482 D1 DE 69635482D1 DE 69635482 T DE69635482 T DE 69635482T DE 69635482 T DE69635482 T DE 69635482T DE 69635482 D1 DE69635482 D1 DE 69635482D1
Authority
DE
Germany
Prior art keywords
mowering
primers
proof
samples
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635482T
Other languages
English (en)
Other versions
DE69635482T2 (de
Inventor
G Korneluk
E Mackenzie
Stephen Baird
Peter Liston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Ottawa
Original Assignee
University of Ottawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/511,485 external-priority patent/US5919912A/en
Application filed by University of Ottawa filed Critical University of Ottawa
Application granted granted Critical
Publication of DE69635482D1 publication Critical patent/DE69635482D1/de
Publication of DE69635482T2 publication Critical patent/DE69635482T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
DE69635482T 1995-08-04 1996-08-05 Säugetieren apoptosis inhibitorprotein genfamilie, primers, probes und verfahren zur nachweis Expired - Lifetime DE69635482T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US511485 1995-08-04
US08/511,485 US5919912A (en) 1995-08-04 1995-08-04 Mammalian IAP antibodies and diagnostic kits
US576956 1995-12-22
US08/576,956 US6156535A (en) 1995-08-04 1995-12-22 Mammalian IAP gene family, primers, probes, and detection methods
PCT/IB1996/001022 WO1997006255A2 (en) 1995-08-04 1996-08-05 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods

Publications (2)

Publication Number Publication Date
DE69635482D1 true DE69635482D1 (de) 2005-12-29
DE69635482T2 DE69635482T2 (de) 2006-07-13

Family

ID=27057240

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635482T Expired - Lifetime DE69635482T2 (de) 1995-08-04 1996-08-05 Säugetieren apoptosis inhibitorprotein genfamilie, primers, probes und verfahren zur nachweis

Country Status (8)

Country Link
US (17) US6156535A (de)
EP (2) EP0837939B1 (de)
JP (1) JP4458551B2 (de)
AT (1) ATE310819T1 (de)
CA (1) CA2228635C (de)
DE (1) DE69635482T2 (de)
ES (1) ES2253756T3 (de)
WO (1) WO1997006255A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073159A1 (en) * 1992-05-11 2003-04-17 Human Genome Sciences, Inc. Human inhibitor of apoptosis gene 1
US5958771A (en) * 1998-12-03 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of cellular inhibitor of Apoptosis-2 expression
US6087173A (en) * 1999-09-09 2000-07-11 Isis Pharmaceuticals Inc. Antisense modulation of X-linked inhibitor of apoptosis expression
US6156535A (en) * 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
AUPN727595A0 (en) * 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic compositions
GB9601108D0 (en) * 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)
WO1997035589A1 (en) * 1996-03-26 1997-10-02 Kopreski Michael S Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
EP0840617B1 (de) * 1996-04-26 2008-06-18 University Of Ottawa Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen
US6511828B1 (en) 1996-05-31 2003-01-28 Arch Development Corporation Human and drosophila inhibitors of apoptosis proteins (IAPs)
US5840535A (en) * 1997-06-02 1998-11-24 Incyte Pharmaceuticals, Inc. DNA encoding a zinc ring protein
US6326481B1 (en) 1998-06-02 2001-12-04 Millennium Pharmaceuticals. Inc. Molecules of the AIP-related protein family and uses thereof
US6171821B1 (en) * 1998-07-24 2001-01-09 Apoptogen, Inc. XIAP IRES and uses thereof
US6472172B1 (en) 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
US20080261292A1 (en) * 1998-09-22 2008-10-23 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
CN1301769A (zh) * 1999-12-29 2001-07-04 复旦大学 一种新的多肽——人的1atexin蛋白46和编码这种多肽的多核苷酸
ATE428116T1 (de) * 2000-06-16 2009-04-15 Rudel Thomas Dr Verfahren zur identifizierung wahrend der apoptose modifizierter proteine
EP1164374A1 (de) * 2000-06-16 2001-12-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Identifizierung während der Apoptose modifizierter Proteine
US20030077590A1 (en) * 2000-09-22 2003-04-24 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US20030044803A1 (en) * 2000-09-22 2003-03-06 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US6673917B1 (en) 2000-09-28 2004-01-06 University Of Ottawa Antisense IAP nucleic acids and uses thereof
US6901173B2 (en) * 2001-04-25 2005-05-31 Lockheed Martin Corporation Scene-based non-uniformity correction for detector arrays
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US7820132B2 (en) * 2001-12-14 2010-10-26 Alliance For Sustainable Energy, Llc Hot wire production of single-wall and multi-wall carbon nanotubes
EP1539189A4 (de) * 2002-03-25 2007-05-09 Univ Boston Verfahren zur verwendung von anti-apoptose-faktoren in der genexpression
EP1490490B1 (de) * 2002-03-27 2009-05-13 Aegera Therapeutics Inc. Gegen iap gerichtete antisense-nukleobasen und deren verwendungen
US20050233411A9 (en) * 2003-02-07 2005-10-20 Chunying Du Compositions and methods for cleaving IAP
US20050019806A1 (en) * 2003-06-30 2005-01-27 Horvitz H. Robert Nucleic acids and polypeptides required for cell survival in the absence of Rb
US8012944B2 (en) * 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
US8017385B2 (en) * 2004-10-22 2011-09-13 Neurologix, Inc. Use of apotosis inhibiting compounds in degenerative neurological disorders
ES2429564T3 (es) 2005-05-18 2013-11-15 Novartis Ag Procedimientos para el diagnóstico y tratamiento de enfermedades que tienen un componente autoinmune y/o inflamatorio
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
EP2534170B1 (de) 2010-02-12 2017-04-19 Pharmascience Inc. Iap-bir-domänen bindende verbindungen
KR101215201B1 (ko) 2010-07-21 2012-12-26 단국대학교 산학협력단 Ｘｉａｐ 단백질을 포함하는 허혈성 질환을 치료 또는 예방하기 위한 조성물
US20140127438A1 (en) 2012-11-08 2014-05-08 Robert L. Sherman, Jr. Stabilized high-density polyethylene composition with improved resistance to deterioration and stabilizer system

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665550A (en) * 1990-10-19 1997-09-09 Board Of Trustees Of The University Of Illinois-Urbana Genes and genetic elements associated with sensitivity to chemotherapeutic drugs
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5594076A (en) * 1991-09-24 1997-01-14 The Pennsylvania Research Foundation Hydrodegradable polyesters
US6265157B1 (en) 1991-12-03 2001-07-24 Allegheny University Of The Health Sciences Compositions and methods for detecting altered COL1A1 gene sequences
US20030073159A1 (en) * 1992-05-11 2003-04-17 Human Genome Sciences, Inc. Human inhibitor of apoptosis gene 1
CA2123406A1 (en) * 1992-09-14 1994-03-31 Katia Georgopoulos Ikaros: a t cell pathway regulatory gene
US6087173A (en) 1999-09-09 2000-07-11 Isis Pharmaceuticals Inc. Antisense modulation of X-linked inhibitor of apoptosis expression
US5958772A (en) 1998-12-03 1999-09-28 Isis Pharmaceuticals Inc. Antisense inhibition of cellular inhibitor of apoptosis-1 expression
US5958771A (en) 1998-12-03 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of cellular inhibitor of Apoptosis-2 expression
WO1994023760A1 (en) * 1993-04-14 1994-10-27 The United States Of America As Represented By The Secretary Of The Navy Transgenic animal model for autoimmune diseases
US5691179A (en) * 1993-08-26 1997-11-25 Washington University Cell death regulators
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
ATE310812T1 (de) * 1994-01-18 2005-12-15 Scripps Research Inst Derivate von zinkfingerproteinen und methoden
WO1995028497A1 (en) * 1994-04-13 1995-10-26 La Jolla Cancer Research Foundation Interaction of proteins involved in a cell death pathway
CZ329596A3 (en) 1994-05-10 1997-05-14 Immulogic Pharma Corp Preparation for treating scattered sclerosis
DE69534720D1 (de) 1994-10-18 2006-02-02 Univ Ottawa Neuronales apotose-inhibitor protein, gen sequenz und mutationen die wirbelsäulenmuskelatrophie verursachen
WO1996012737A2 (en) 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
AU4695296A (en) 1995-01-06 1996-07-24 Immulogic Pharmaceutical Corporation Compositions and methods for treating rheumatoid arthritis
AU2548095A (en) 1995-05-11 1996-11-29 Human Genome Sciences, Inc. Human inhibitor of apoptosis gene 1
US5770690A (en) * 1995-06-27 1998-06-23 Neurex Corporation Bax omega protein and methods
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US6156535A (en) * 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US5919912A (en) * 1995-08-04 1999-07-06 University Of Ottawa Mammalian IAP antibodies and diagnostic kits
AU6692996A (en) 1995-08-08 1997-03-05 Tularik Inc. Inhibitors of apoptosis
US6187557B1 (en) 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
US5834216A (en) * 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
AUPN727595A0 (en) * 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic compositions
US5605022A (en) * 1995-12-26 1997-02-25 Nci Building Systems, Inc. Vented closure
GB9601108D0 (en) * 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
JP3493400B2 (ja) * 1996-06-24 2004-02-03 タカラバイオ株式会社 新規なアミノ末端保護基遊離酵素
AU5065098A (en) 1996-11-15 1998-06-10 University Of Ottawa Modulators of ovarial apoptosis related to iap
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US6228603B1 (en) 1997-05-22 2001-05-08 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
CA2225187A1 (en) * 1997-07-14 1999-01-14 Universite D'ottawa/ University Of Ottawa Xaf genes and polypeptides: methods and reagents for modulating apoptosis
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
AU1080899A (en) 1997-10-14 1999-05-03 Nadine A. Tatton Methods for increasing schwann cell survival
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6171821B1 (en) 1998-07-24 2001-01-09 Apoptogen, Inc. XIAP IRES and uses thereof
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6492427B2 (en) * 1998-10-09 2002-12-10 L. Sai Latha Shankar Methods for treating multiple sclerosis
US6187657B1 (en) * 1999-03-24 2001-02-13 Advanced Micro Devices, Inc. Dual material gate MOSFET technique
KR20000065690A (ko) 1999-04-08 2000-11-15 박종구 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US6395771B1 (en) 2000-05-31 2002-05-28 Dabur Research Foundation Paclitaxel derivatives for the treatment of cancer
US6673917B1 (en) * 2000-09-28 2004-01-06 University Of Ottawa Antisense IAP nucleic acids and uses thereof
US20020119168A1 (en) * 2001-02-20 2002-08-29 Rudnic Edward M. Therapeutic agent delivery
KR100397275B1 (ko) * 2001-03-08 2003-09-17 주식회사 웰진 단방향성 안티센스 ｃＤＮＡ 라이브러리 구축을 통한 신규대규모 유전자 검색 및 기능 분석 시스템
AU2003228301A1 (en) 2002-03-06 2003-09-22 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of sirna molecules
EP1490490B1 (de) 2002-03-27 2009-05-13 Aegera Therapeutics Inc. Gegen iap gerichtete antisense-nukleobasen und deren verwendungen
EP1469070A1 (de) 2003-04-15 2004-10-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Livinspezifische SiRNAs zur Behandlung von therapie-resistente Tumoren
EP1668024A4 (de) * 2003-09-29 2008-07-02 Topigen Pharma Inc Oligonukleotidzusammensetzungen und verfahren zur behandlung von krankheiten einschliesslich entzündlicher leiden
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
US6946917B2 (en) * 2003-11-25 2005-09-20 Texas Instruments Incorporated Generating an oscillating signal according to a control current

Also Published As

Publication number Publication date
US7776552B2 (en) 2010-08-17
US20070031903A1 (en) 2007-02-08
US6156535A (en) 2000-12-05
US6656704B1 (en) 2003-12-02
EP1757689A3 (de) 2007-05-23
EP0837939B1 (de) 2005-11-23
US20070031904A1 (en) 2007-02-08
US20060127927A1 (en) 2006-06-15
EP0837939A2 (de) 1998-04-29
US20070026494A1 (en) 2007-02-01
US6689562B1 (en) 2004-02-10
DE69635482T2 (de) 2006-07-13
US20060205021A1 (en) 2006-09-14
US20070027304A1 (en) 2007-02-01
US20070009971A1 (en) 2007-01-11
EP1757689A2 (de) 2007-02-28
ATE310819T1 (de) 2005-12-15
CA2228635A1 (en) 1997-02-20
US20070042446A1 (en) 2007-02-22
US6977158B1 (en) 2005-12-20
JP4458551B2 (ja) 2010-04-28
US20070026470A1 (en) 2007-02-01
CA2228635C (en) 2002-11-26
US20070066524A1 (en) 2007-03-22
ES2253756T3 (es) 2006-06-01
US7067281B2 (en) 2006-06-27
WO1997006255A3 (en) 1997-10-30
US20020187946A1 (en) 2002-12-12
WO1997006255A2 (en) 1997-02-20
US6541457B2 (en) 2003-04-01
US20040157232A1 (en) 2004-08-12
JPH11511013A (ja) 1999-09-28
US20070048772A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
DE69635482D1 (de) Säugetieren apoptosis inhibitorprotein genfamilie, primers, probes und verfahren zur nachweis
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
ATE378417T1 (de) Polymerase-verbessernder faktor (pef)-enthaltende extrakte, pef proteinkomplexe, isoliertes pef protein und verfahren zur reinigung und identifizierung
Azen Genetic protein polymrophisms in human saliva: An interpretive review
AU4148685A (en) Single strands nucleic acid as hybridation probe
WO1999064592A3 (en) Green fluorescent proteins for measuring the ph of a biological sample
DE69808743T2 (de) Netrinrezeptoren
DE3587875T3 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
DE69826493D1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
ATE245190T1 (de) Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
ATE224953T1 (de) Paraoxonase aus serum
DK71986A (da) Polypeptider fra rhinovirusstamme hrv2 samt de herfor kodende dna-molekyler, fremgangsmaade til polypeptidernes fremstilling og deres anvendelse
Cahill et al. Isolation and characterization of rat liver mitochondrial ribosomes
DE69718052T2 (de) Menschliches wachstumsgen und minderwuchse gen bereich
GR3029811T3 (en) Dna encoding cai resistance proteins and uses thereof
AU4981093A (en) Nucleotide sequences coding for cryptosporidium proteins, polypeptides coded by said sequences and kits for the use thereof
ATE315107T1 (de) Verfahren und kit zur früherkennung von krebs
WO2003044170A3 (en) Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
WO2000021984A3 (en) Nucleic acids encoding human cide-b protein and polymorphic markers thereof
EP1241269A3 (de) Verfahren zum Nachweiss von REG-ähnliches Protein und dafür kodierende Nukleinäuren
Juretic Mitochondrial DNA rearrangements: intracellular information system
WO2002022823A3 (de) An der stressantwort beteiligte proteine und dafür codierende gene aus ashbya gossypii
LANGLEY TWO-DIMENSIONAL ELECTROPHORETIC ANALYSIS OF MICROSPORIDAN SPORE PROTEINS.
DE69840790D1 (de) TUMOR-OBERFLÄCHENPROTEIN UND SEIN ENTSPRECHENDER OBERFLÄCHENREZEPTOR AUF NATÜRLICHEN KILLERZELLEn

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: HEYER, V., DIPL.-PHYS. DR.RER.NAT., PAT.-ANW., 806